Illumina, Inc.


SKU: ILMN Category:


This is our first report on Illumina, a well-known provider of sequencing and array-based solutions for genetic and genomic analysis. The company had a great quarter with growth in revenue on part with Wall Street expectations in spite of macroeconomic challenges. In the quarter, Illumina saw fantastic customer response to the recently launched NovaSeq X Series. The company shipped 65 NovaSeq 6000 and the manufacturing scaling is proceeding well. It also launched the first-ever CE-marked and FDA-registered IVD high-throughput sequencer, NovaSeq 6000 DX. In mid-throughput, Illumina saw a record NextSeq 2K, 1K shipments. Driven by genetic disease testing and oncology testing, there was an increase in clinical sequencing consumable shipments. In this quarter, Grail also continued to make quite great progress. GRAIL announced a first-of-its-kind collaboration with the first digital health company Karim Health. Illumina also managed to deliver an earnings beat. The company has recently announced an innovative research test for identifying AMR (Antimicrobial Resistance) and genitourinary pathogen infection. Also, Illumina announced a collaboration with General screen for helping countries that are impacted by tuberculosis to detect and combat multidrug-resistant strains more effectively. We initiate coverage on the stock of Illumina with a ‘Hold’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!